
-
Annexon Inc. NasdaqGS:ANNX Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Location: 1400 Sierra Point Parkway, Brisbane, CA, 94005, United States | Website: https://www.annexonbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-14.86M
Cash
263.7M
Avg Qtr Burn
-34.95M
Short % of Float
12.09%
Insider Ownership
0.57%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ANX005 (IV) Details Guillian-Barre syndrome, Autoimmune disease | BLA Submission | |
ANX007 (IVT) Details Geographic atrophy | Phase 3 Data readout | |
ANX005 (IV) Details Huntington's disease, Brain disease | Phase 3 Initiation | |
ANX005 (IV) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Phase 2a Update | |
ANX009 Details Lupus nephritis | Phase 1b Update | |
ANX105 Details Autoimmune disease, Neurodegenerative disease | Phase 1 Data readout | |
ANX1502 Details Cold agglutinin disease | Phase 1a Data readout | |
ANX005 (IV) Details Warm autoimmune hemolytic anemia, Autoimmune disease | Failed Discontinued |